We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination.
- Authors
Ogawa, Haruki; Abe, Hiroyuki; Yagi, Koichi; Seto, Yasuyuki; Ushiku, Tetsuo
- Abstract
Background: Gastric cancer with peritoneal dissemination (PD) has a dismal prognosis, and current treatments have shown little efficacy. CLDN18.2-targeted therapies have shown promising efficacy against gastric cancers that express high levels of CLDN18. Because of the limited information regarding CLDN18.2 status in PD, we analyzed PD-positive gastric cancers for CLDN18 status in both primary and PD, along with HER2 and PD-L1 combined positive score (CPS). Methods: Immunohistochemical analyses were performed on 84 gastric cancer cases using paired primary and PD tissue samples. Results: At 40% cut-off, CLDN18 was positive in 57% (48/84) primary tumors and in 44% (37/84) PDs. At 75% cut-off, 28.6% (24/84) primary tumors and 20.2% (17/84) PDs were CLDN18-positive. The concordance rate between primary tumors and PD was 79.8% at 40% cut-off and 75% at 75% cut-off. When comparing biopsy and surgical specimens, the concordance rates were 87.5% at 40% cut-off and 81.3% at 75% cut-off. Within a tumor, the superficial area tended to have a higher CLDN18-positive rate than the invasive front (P = 0.001). Although HER2 -positivity was only 11.9% in this cohort, CLDN18 positivity in HER2-negative tumors (n = 74) was relatively high: 60.8% at 40% cut-off and 28.4% at 75% cut-off. Among double-negative (HER2 − and PD-L1 CPS < 1) tumors, CLDN18 positivity was 67.6% at 40% cut-off and 26.5% at 75% cut-off. Conclusions: CLDN18 expression is generally maintained in PD and is relatively high even in double-negative tumors, making it a promising therapeutic target for PD-positive gastric cancer.
- Subjects
STOMACH cancer; CANCER invasiveness; PROGRAMMED death-ligand 1; IMMUNOHISTOCHEMISTRY; PERITONEAL cancer; PROGNOSIS
- Publication
Gastric Cancer, 2024, Vol 27, Issue 4, p802
- ISSN
1436-3291
- Publication type
Article
- DOI
10.1007/s10120-024-01505-6